Skip Navigation

Link to  the National Institutes of Health  
The Science of Drug Abuse and Addiction from the National Institute on Drug Abuse Archives of the National Institute on Drug Abuse web site
Go to the Home page
   

Home > Publications > Research Monographs >    

Discovery of Novel Opioid Medications



NIDA Research Monograph, Number 147 [Printed in 1995]

Get Adobe Reader

This monograph is not available by chapter. The Table of Contents (below) is shown to assist in locating information prior to downloading the monograph.

Download Monograph147.pdf - Discovery of Novel Opioid Medications (2.1 MB)


Table of Contents

Introduction-----v
Rao S. Rapaka and Heinz Sorer

Targeting Drugs to the Brain by Sequential Metabolism-----1
Nicholas Bodor

Action of Opioid Drugs on the Brain-Reward System-----33
Conan Kornetsky

Drugs That Modify Opioid Tolerance, Physical Dependence, and Abstinence Symptoms: Preclinical and Clinical Studies-----53
Hemendra N. Bhargava

Future Directions in the Pharmacological Management of Hyperalgesic and Allodynic Pain States: The NMDA Receptor-----84
Tony L. Yaksh, Sandra R. Chaplan, and Annika B. Malmberg

Dual Inhibitors of Enkephalin-Degrading Enzymes (Neutral Endopeptidase 24.11 and Aminopeptidase N) as Potential New Medications in the Management of Pain and Opioid Addiction-----104
Bernard P. Rogues and Florence Noble

Enhanced N-Methyl-D-Aspartate (NMDA)-Induced Activity Following Morphine: Sensitivity to Sigma and PCP Ligands-----146
Alice A. Larson, Rustam Yu. Yukhananov, and Julie S. Kreeger

Dynorphin A: A Rectifying Peptide-----161
Nancy M. Lee

Inhibitors of Nitric Oxide Synthase and the Opioid Withdrawal Syndrome-----170
Edythe D. London, Alane S. Kimes, and D. Bruce Vaupel

Nitric Oxide and Opioid Tolerance-----182
Gavril W. Pasternak

Methoclocinnamox: A Partial Agonist With Pharmacotherapeutic Potential for Heroin Abuse-----195
James H. Woods, John W. Lewis, Gail Winger, Eduardo Butelman, Jillian Broadbear, and Gerald Zernig

ACEA-1011, a Novel NMDA Receptor/Glycine Site Antagonist, Produces Antinociception but Not Tolerance in the Formalin Test in Mice-----220
Kabirullah Lutfy, John F. W. Keana, and Eckard Weber

Etorphine Elicits Unique Inhibitory-Agonist and Excitatory-Antagonist Actions at Opioid Receptors on Sensory Neurons: New Rationale for Improved Clinical Analgesia and Treatment of Opiate Addiction-----234
Stanley M. Crain and Ke-Fei Shen

The Association of Neuropathic Pain, Morphine Tolerance and Dependence, and the Translocation of Protein Kinase C-----269
David J. Mayer, Jianren Mao, and Donald D. Price




Archive Home | Accessibility | Privacy | FOIA (NIH) | Current NIDA Home Page
National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. . The U.S. government's official web portal